Risultati preliminari dell’utilizzo di rufinamide in add-on su un campione di soggetti affetti da Sindrome di Lennox-Gastaut.

Rufinamide is a new anti-epileptic drug used as adjunctive treatment of Lennox-Gastaut syndrome. The aim of the study was to give preliminary data about effectiveness and tolerability of rufinamide in a group of patients affected with Lennox-Gastaut syndrome and presenting with refractory seizures.